3 results
Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet andincreased physical activity in participants with overweight or obesity. Secondary To confirm superiority of…
Part 1: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to…
The primary objective of this study is to evaluate the effect of FES on participation level: achieving of individual goals, using the goal attainment scale (GAS)), and the Canadian Occupational Performance Measure (COPM) for the long term. Secondary…